Potential Mechanistic Investigation of Bromhexine for the Treatment of COVID-19

Yong Yang, Hao Shen, S. Zhao, Dong Wang, Hao Wang
{"title":"Potential Mechanistic Investigation of Bromhexine for the Treatment of COVID-19","authors":"Yong Yang, Hao Shen, S. Zhao, Dong Wang, Hao Wang","doi":"10.11669/CPJ.2020.09.003","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To investigate antiviral mechanism of bromhexine for the treatment of COVID-19. METHODS: Based on the existing literature, the infection pathways of new coronavirus(SARS-CoV-2) were systematically summarized by us, and used the SWISSDOCK molecular simulation method to carry out virtual screen systematically for key targets and marketed drugs. RESULTS: TMPRSS2/ACE2 pathway was found to be the most efficient and probably the major pathway for SARS-CoV-2 virus to infect the lung and other tissue by us. Bromhexine, an expectorant, can strongly inhibit TMPRSS2 protease (EC 50:0.75 μmol•L -1) in vitro. Bromhexine has few adverse effects and also has the beneficial effects of promoting the release and maintenance of endogenous active substances in the lung, alveolar function, and promoting sputum excretion, which is suitable for use together with other COVID19 medication and therapies. CONCLUSION: Bromhexine has a unique potential antiviral mechanism, and clinical research should be conducted to play its role in the prevention, treatment and prognosis of COVID19.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Chinese Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11669/CPJ.2020.09.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

OBJECTIVE: To investigate antiviral mechanism of bromhexine for the treatment of COVID-19. METHODS: Based on the existing literature, the infection pathways of new coronavirus(SARS-CoV-2) were systematically summarized by us, and used the SWISSDOCK molecular simulation method to carry out virtual screen systematically for key targets and marketed drugs. RESULTS: TMPRSS2/ACE2 pathway was found to be the most efficient and probably the major pathway for SARS-CoV-2 virus to infect the lung and other tissue by us. Bromhexine, an expectorant, can strongly inhibit TMPRSS2 protease (EC 50:0.75 μmol•L -1) in vitro. Bromhexine has few adverse effects and also has the beneficial effects of promoting the release and maintenance of endogenous active substances in the lung, alveolar function, and promoting sputum excretion, which is suitable for use together with other COVID19 medication and therapies. CONCLUSION: Bromhexine has a unique potential antiviral mechanism, and clinical research should be conducted to play its role in the prevention, treatment and prognosis of COVID19.
溴甲基辛治疗COVID-19的潜在机制研究
目的:探讨溴克辛治疗COVID-19的抗病毒机制。方法:我们在现有文献的基础上,系统总结新型冠状病毒(SARS-CoV-2)的感染途径,并利用SWISSDOCK分子模拟方法对关键靶点和上市药物进行系统的虚拟筛选。结果:我们发现TMPRSS2/ACE2途径是SARS-CoV-2病毒感染肺部和其他组织最有效的途径,可能是其主要途径。祛痰剂溴己辛在体外对TMPRSS2蛋白酶有较强的抑制作用(EC 50:0.75 μmol•L -1)。溴克辛不良反应少,还具有促进肺部内源性活性物质释放和维持、肺泡功能、促进痰液排泄的有益作用,适合与其他covid - 19药物和疗法合用。结论:溴甲基辛具有独特的潜在抗病毒机制,应开展临床研究,以发挥其在covid - 19的预防、治疗和预后中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信